Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioma | 41 | 2025 | 3502 | 4.830 |
Why?
|
Brain Neoplasms | 43 | 2025 | 9108 | 3.230 |
Why?
|
Cerebellar Neoplasms | 5 | 2024 | 590 | 1.970 |
Why?
|
Medulloblastoma | 5 | 2024 | 682 | 1.670 |
Why?
|
Ependymoma | 4 | 2021 | 328 | 1.580 |
Why?
|
Central Nervous System Neoplasms | 4 | 2024 | 928 | 1.240 |
Why?
|
Azepines | 4 | 2019 | 329 | 1.100 |
Why?
|
Brain Stem Neoplasms | 6 | 2024 | 191 | 0.950 |
Why?
|
Triazoles | 4 | 2019 | 903 | 0.870 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2022 | 137 | 0.720 |
Why?
|
Astrocytoma | 6 | 2023 | 773 | 0.720 |
Why?
|
Oncogenes | 3 | 2022 | 1232 | 0.650 |
Why?
|
Child | 53 | 2025 | 80771 | 0.640 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2019 | 1608 | 0.630 |
Why?
|
Population Control | 1 | 2017 | 23 | 0.570 |
Why?
|
Mutation | 21 | 2024 | 30211 | 0.570 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 498 | 0.540 |
Why?
|
Interneurons | 2 | 2020 | 592 | 0.520 |
Why?
|
Oncogene Proteins v-myb | 1 | 2016 | 26 | 0.520 |
Why?
|
Cell Cycle | 3 | 2022 | 2927 | 0.500 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2024 | 2058 | 0.480 |
Why?
|
RNA-Binding Proteins | 4 | 2025 | 1889 | 0.460 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2013 | 33 | 0.440 |
Why?
|
Proto-Oncogene Proteins c-myc | 3 | 2019 | 998 | 0.430 |
Why?
|
Neurogenesis | 1 | 2019 | 863 | 0.410 |
Why?
|
Optic Nerve Glioma | 1 | 2012 | 32 | 0.400 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2025 | 9410 | 0.380 |
Why?
|
Molecular Targeted Therapy | 8 | 2024 | 2824 | 0.340 |
Why?
|
Eye Abnormalities | 1 | 2012 | 243 | 0.340 |
Why?
|
Histones | 4 | 2024 | 2597 | 0.310 |
Why?
|
Proteins | 3 | 2021 | 6001 | 0.310 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2952 | 0.300 |
Why?
|
Neural Stem Cells | 3 | 2020 | 895 | 0.300 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2025 | 8628 | 0.300 |
Why?
|
Optic Disk | 1 | 2012 | 421 | 0.300 |
Why?
|
Humans | 84 | 2025 | 767040 | 0.290 |
Why?
|
Transcription Factors | 6 | 2025 | 12158 | 0.290 |
Why?
|
Pathology, Molecular | 2 | 2023 | 328 | 0.290 |
Why?
|
Cell Cycle Proteins | 6 | 2022 | 3440 | 0.290 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2024 | 5332 | 0.290 |
Why?
|
Child, Preschool | 18 | 2025 | 42606 | 0.290 |
Why?
|
Neoplasms | 9 | 2025 | 22350 | 0.280 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2024 | 3667 | 0.280 |
Why?
|
Oligodendroglia | 4 | 2020 | 539 | 0.280 |
Why?
|
Nuclear Proteins | 4 | 2014 | 5794 | 0.280 |
Why?
|
Infant | 16 | 2025 | 36485 | 0.280 |
Why?
|
DNA Copy Number Variations | 4 | 2025 | 2047 | 0.280 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 1253 | 0.270 |
Why?
|
Forkhead Transcription Factors | 2 | 2025 | 1626 | 0.260 |
Why?
|
Cell Line, Tumor | 13 | 2025 | 17097 | 0.260 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 2 | 2022 | 361 | 0.260 |
Why?
|
Gene Amplification | 2 | 2025 | 1088 | 0.250 |
Why?
|
Hedgehog Proteins | 2 | 2024 | 771 | 0.250 |
Why?
|
Spinal Neoplasms | 1 | 2011 | 714 | 0.230 |
Why?
|
Neuroblastoma | 2 | 2025 | 1266 | 0.220 |
Why?
|
Genome, Human | 4 | 2021 | 4441 | 0.220 |
Why?
|
Fibroblasts | 1 | 2013 | 4167 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2024 | 13650 | 0.210 |
Why?
|
Gene Dosage | 3 | 2017 | 1211 | 0.210 |
Why?
|
DNA Damage | 3 | 2025 | 2469 | 0.200 |
Why?
|
Carboplatin | 2 | 2019 | 790 | 0.200 |
Why?
|
RNA | 2 | 2023 | 2715 | 0.200 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2020 | 367 | 0.190 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3608 | 0.190 |
Why?
|
Craniopharyngioma | 1 | 2024 | 279 | 0.190 |
Why?
|
Consensus | 4 | 2024 | 3207 | 0.190 |
Why?
|
Cloning, Organism | 1 | 2020 | 50 | 0.180 |
Why?
|
Genomics | 4 | 2024 | 5924 | 0.180 |
Why?
|
Epigenesis, Genetic | 6 | 2022 | 3828 | 0.180 |
Why?
|
INDEL Mutation | 2 | 2020 | 266 | 0.180 |
Why?
|
Medical Oncology | 2 | 2024 | 2341 | 0.170 |
Why?
|
Adolescent | 18 | 2025 | 89046 | 0.170 |
Why?
|
Cell Survival | 5 | 2024 | 5750 | 0.170 |
Why?
|
Delphi Technique | 1 | 2024 | 891 | 0.170 |
Why?
|
Cell Lineage | 4 | 2025 | 2575 | 0.170 |
Why?
|
Cyclin D2 | 1 | 2019 | 97 | 0.160 |
Why?
|
Combined Modality Therapy | 4 | 2023 | 8535 | 0.160 |
Why?
|
Mice | 15 | 2025 | 81912 | 0.160 |
Why?
|
Molecular Biology | 1 | 2022 | 573 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 115 | 0.150 |
Why?
|
Disease-Free Survival | 4 | 2018 | 6844 | 0.150 |
Why?
|
Treatment Outcome | 6 | 2024 | 65295 | 0.150 |
Why?
|
Comparative Genomic Hybridization | 2 | 2017 | 474 | 0.150 |
Why?
|
S Phase | 1 | 2019 | 424 | 0.150 |
Why?
|
Magnetic Resonance Imaging | 4 | 2025 | 36582 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2020 | 385 | 0.150 |
Why?
|
Glioblastoma | 2 | 2023 | 3461 | 0.150 |
Why?
|
Genomic Structural Variation | 1 | 2018 | 80 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2017 | 82 | 0.140 |
Why?
|
Indazoles | 1 | 2018 | 306 | 0.140 |
Why?
|
Epigenomics | 1 | 2022 | 959 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11872 | 0.140 |
Why?
|
Neurocytoma | 1 | 2016 | 28 | 0.130 |
Why?
|
Transcription, Genetic | 4 | 2020 | 7611 | 0.130 |
Why?
|
ADP-Ribosylation Factor 1 | 1 | 2016 | 43 | 0.130 |
Why?
|
Glutathione | 1 | 2019 | 589 | 0.130 |
Why?
|
Proto-Oncogene Proteins | 2 | 2022 | 4522 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2019 | 352 | 0.130 |
Why?
|
Animals | 19 | 2025 | 168965 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1142 | 0.130 |
Why?
|
Autopsy | 1 | 2019 | 1011 | 0.130 |
Why?
|
Receptor, trkB | 1 | 2016 | 123 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2016 | 205 | 0.120 |
Why?
|
Pituitary Neoplasms | 1 | 2024 | 1322 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2019 | 562 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 18063 | 0.120 |
Why?
|
Publications | 1 | 2017 | 195 | 0.120 |
Why?
|
Pyridones | 1 | 2020 | 819 | 0.120 |
Why?
|
Apoptosis | 4 | 2023 | 9513 | 0.120 |
Why?
|
Follow-Up Studies | 7 | 2025 | 39317 | 0.120 |
Why?
|
Genomic Instability | 1 | 2018 | 716 | 0.110 |
Why?
|
Male | 24 | 2025 | 364203 | 0.110 |
Why?
|
Daunorubicin | 1 | 2013 | 157 | 0.110 |
Why?
|
Recurrence | 2 | 2023 | 8504 | 0.110 |
Why?
|
Chromatin | 2 | 2022 | 2980 | 0.110 |
Why?
|
Histone Deacetylases | 1 | 2018 | 712 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 777 | 0.110 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 1144 | 0.100 |
Why?
|
Female | 25 | 2025 | 396660 | 0.100 |
Why?
|
Cell Proliferation | 6 | 2022 | 10455 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2023 | 1244 | 0.100 |
Why?
|
Chromosome Mapping | 1 | 2021 | 4616 | 0.100 |
Why?
|
Astrocytes | 2 | 2020 | 1352 | 0.100 |
Why?
|
HEK293 Cells | 1 | 2022 | 4280 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1319 | 0.100 |
Why?
|
Retrospective Studies | 11 | 2025 | 81659 | 0.100 |
Why?
|
SEER Program | 1 | 2017 | 1444 | 0.100 |
Why?
|
Survival Rate | 3 | 2025 | 12823 | 0.100 |
Why?
|
Radiation Tolerance | 1 | 2013 | 476 | 0.090 |
Why?
|
Second-Look Surgery | 1 | 2011 | 27 | 0.090 |
Why?
|
Young Adult | 8 | 2024 | 59980 | 0.090 |
Why?
|
Survival Analysis | 3 | 2021 | 10092 | 0.090 |
Why?
|
Open Reading Frames | 2 | 2025 | 818 | 0.090 |
Why?
|
Gene Rearrangement | 1 | 2016 | 1141 | 0.090 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2014 | 488 | 0.090 |
Why?
|
Publishing | 1 | 2017 | 837 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8048 | 0.090 |
Why?
|
Pilot Projects | 1 | 2023 | 8732 | 0.090 |
Why?
|
Adult | 13 | 2022 | 223317 | 0.090 |
Why?
|
Evolution, Molecular | 1 | 2018 | 1893 | 0.080 |
Why?
|
NF-kappa B | 1 | 2018 | 2493 | 0.080 |
Why?
|
Etoposide | 1 | 2011 | 639 | 0.080 |
Why?
|
Mice, Inbred NOD | 1 | 2013 | 1837 | 0.080 |
Why?
|
Melphalan | 1 | 2011 | 421 | 0.080 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2902 | 0.080 |
Why?
|
Brain | 5 | 2023 | 27163 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1982 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3599 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9532 | 0.080 |
Why?
|
Mice, SCID | 1 | 2013 | 2626 | 0.080 |
Why?
|
Vincristine | 1 | 2011 | 1040 | 0.080 |
Why?
|
Mice, Nude | 3 | 2019 | 3618 | 0.070 |
Why?
|
Retinal Detachment | 1 | 2012 | 429 | 0.070 |
Why?
|
Phosphoproteins | 1 | 2017 | 2448 | 0.070 |
Why?
|
Spinal Cord | 1 | 2016 | 1811 | 0.070 |
Why?
|
Registries | 3 | 2022 | 8351 | 0.070 |
Why?
|
DNA Mismatch Repair | 2 | 2021 | 431 | 0.070 |
Why?
|
Immunotherapy | 2 | 2024 | 4745 | 0.070 |
Why?
|
Arousal | 2 | 2002 | 1174 | 0.070 |
Why?
|
Rhabdoid Tumor | 1 | 2008 | 211 | 0.070 |
Why?
|
Prognosis | 7 | 2025 | 29963 | 0.070 |
Why?
|
Clone Cells | 2 | 2020 | 1669 | 0.060 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 2118 | 0.060 |
Why?
|
Cells, Cultured | 3 | 2020 | 18989 | 0.060 |
Why?
|
Membrane Glycoproteins | 1 | 2016 | 3702 | 0.060 |
Why?
|
Cohort Studies | 2 | 2020 | 41718 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2227 | 0.060 |
Why?
|
Remission Induction | 1 | 2011 | 2408 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2022 | 18330 | 0.060 |
Why?
|
Feasibility Studies | 2 | 2018 | 5311 | 0.060 |
Why?
|
Cisplatin | 1 | 2011 | 1656 | 0.060 |
Why?
|
Signal Transduction | 6 | 2020 | 23621 | 0.060 |
Why?
|
Radiotherapy Dosage | 1 | 2011 | 2915 | 0.060 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2008 | 724 | 0.050 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2019 | 951 | 0.050 |
Why?
|
Sequence Analysis, DNA | 3 | 2020 | 4780 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6611 | 0.050 |
Why?
|
Sudden Infant Death | 2 | 2002 | 293 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 3 | 2024 | 5693 | 0.050 |
Why?
|
Neurons | 2 | 2025 | 9517 | 0.050 |
Why?
|
Visual Acuity | 1 | 2012 | 2714 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2024 | 329 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2011 | 1596 | 0.050 |
Why?
|
DNA Repair Enzymes | 1 | 2024 | 342 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2019 | 4282 | 0.050 |
Why?
|
DNA Repair | 2 | 2024 | 2050 | 0.050 |
Why?
|
Databases, Genetic | 2 | 2020 | 1758 | 0.050 |
Why?
|
Tryptophan | 1 | 2024 | 484 | 0.050 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2024 | 434 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3591 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2022 | 313 | 0.050 |
Why?
|
Disease Management | 2 | 2024 | 2531 | 0.050 |
Why?
|
Gene Knockout Techniques | 1 | 2024 | 804 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2024 | 638 | 0.050 |
Why?
|
5'-Nucleotidase | 1 | 2022 | 163 | 0.050 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9551 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 2509 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2040 | 0.040 |
Why?
|
DNA Breaks | 1 | 2020 | 47 | 0.040 |
Why?
|
Temperament | 1 | 2002 | 301 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 369 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2025 | 13491 | 0.040 |
Why?
|
raf Kinases | 1 | 2019 | 117 | 0.040 |
Why?
|
Biopsy | 2 | 2023 | 6777 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2022 | 2538 | 0.040 |
Why?
|
Prosencephalon | 1 | 2020 | 305 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2019 | 350 | 0.040 |
Why?
|
History, 21st Century | 1 | 2024 | 1574 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 259 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6513 | 0.040 |
Why?
|
Posture | 1 | 2002 | 956 | 0.040 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2020 | 330 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2018 | 66 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 784 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2014 | 4903 | 0.040 |
Why?
|
Adenosine | 1 | 2022 | 812 | 0.040 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2019 | 640 | 0.040 |
Why?
|
Age Factors | 3 | 2019 | 18401 | 0.040 |
Why?
|
Cell Shape | 1 | 2018 | 372 | 0.040 |
Why?
|
Disease Progression | 3 | 2021 | 13646 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2765 | 0.030 |
Why?
|
Protein Biosynthesis | 1 | 2024 | 2093 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2020 | 5796 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1405 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2022 | 1751 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 614 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2018 | 348 | 0.030 |
Why?
|
Lysine | 1 | 2020 | 998 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1227 | 0.030 |
Why?
|
Virus Integration | 1 | 2018 | 307 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2025 | 21178 | 0.030 |
Why?
|
Incidence | 1 | 2014 | 21526 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2012 | 0.030 |
Why?
|
Pediatrics | 2 | 2024 | 3621 | 0.030 |
Why?
|
Ontario | 1 | 2016 | 403 | 0.030 |
Why?
|
Genome | 1 | 2023 | 1752 | 0.030 |
Why?
|
Morpholines | 1 | 2018 | 584 | 0.030 |
Why?
|
Embryo, Mammalian | 1 | 2020 | 1676 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 615 | 0.030 |
Why?
|
Infant, Newborn | 4 | 2024 | 26396 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2024 | 1592 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3344 | 0.030 |
Why?
|
Gene Silencing | 1 | 2020 | 1505 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16718 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2022 | 1672 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 842 | 0.030 |
Why?
|
Sequence Deletion | 1 | 2018 | 1494 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1754 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 705 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3621 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2018 | 1864 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2020 | 14476 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 1492 | 0.020 |
Why?
|
Gene Deletion | 1 | 2020 | 2668 | 0.020 |
Why?
|
Brain Stem | 1 | 2017 | 858 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2025 | 4401 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6106 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2008 | 9612 | 0.020 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2014 | 506 | 0.020 |
Why?
|
Anaplasia | 1 | 2011 | 16 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1814 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3717 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2016 | 940 | 0.020 |
Why?
|
Microglia | 1 | 2019 | 1370 | 0.020 |
Why?
|
RNA Interference | 1 | 2019 | 2829 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2016 | 2920 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2883 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1502 | 0.020 |
Why?
|
Cell Line | 1 | 2023 | 15567 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3944 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2014 | 1228 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2019 | 16036 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2011 | 564 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2568 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11063 | 0.020 |
Why?
|
Blotting, Southern | 1 | 2008 | 775 | 0.020 |
Why?
|
Risk Factors | 2 | 2014 | 74886 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2721 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6893 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3611 | 0.020 |
Why?
|
Ligands | 1 | 2014 | 3273 | 0.020 |
Why?
|
Sleep | 1 | 2002 | 4816 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7435 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3797 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6331 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54886 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2011 | 1836 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9362 | 0.020 |
Why?
|
Pyrimidines | 1 | 2018 | 3044 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3427 | 0.020 |
Why?
|
Survivors | 1 | 2016 | 2381 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2014 | 2744 | 0.020 |
Why?
|
Models, Biological | 1 | 2020 | 9464 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3114 | 0.010 |
Why?
|
Biomedical Research | 1 | 2019 | 3464 | 0.010 |
Why?
|
Software | 1 | 2018 | 4472 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7063 | 0.010 |
Why?
|
Risk Assessment | 1 | 2025 | 24299 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12069 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13485 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 22361 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10622 | 0.010 |
Why?
|
Prone Position | 1 | 2002 | 203 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12536 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11217 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12790 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 8068 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 4114 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20169 | 0.010 |
Why?
|
Polysomnography | 1 | 2002 | 1868 | 0.010 |
Why?
|
United States | 1 | 2022 | 72971 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 40154 | 0.010 |
Why?
|
Infant, Premature | 1 | 2002 | 2125 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2002 | 14766 | 0.000 |
Why?
|